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ABSTRACT Chronic obstructive pulmonary disease (COPD) has extensively been reported as a complex
disease affecting patients’ health beyond the lungs with a variety of intra- and extrapulmonary components
and considerable variability between individuals. This review discusses the assessment of this complexity
and underlines the importance of transdisciplinary management programmes addressing the physical,
emotional and social health of the individual patient.
COPD management is challenging and requires advanced, sophisticated strategies meeting the patient’s
individual needs. Due to the heterogeneity and complexity of the disease leading to non-linear and
consequently poorly predictable treatment responses, multidimensional patient profiling is crucial to
identify the right COPD patient for the right treatment. Current methods are often restricted to general,
well-known and commonly used assessments neglecting potentially relevant (interactions between)
individual, unique “traits” to finally ensure personalised treatment. Dynamic, personalised and holistic
approaches are needed to tackle this multifaceted disease and to ensure personalised medicine and value-
based healthcare.
Introduction
Chronic obstructive pulmonary disease (COPD) has extensively been reported as a complex disease
affecting patients’ health beyond the lungs with a variety of intra- and extrapulmonary components and
considerable variability between individuals [1–6]. Unfortunately, current reductionist approaches of
COPD often ignore this complexity and heterogeneity [7, 8].
The complexity of COPD has already been highlighted, for instance by FREY and SUKI [8] who critically
reviewed reductionist approaches “whereby researchers isolated and identified specific mechanisms from
the complex web of interacting subsystems” and suggested a multidimensional, complex systems approach
also considering the unpredictable nature of COPD. During recent years, multidimensional assessment of
COPD has been increasingly studied as well as (trying to be) incorporated in clinical practice [9–11].
Unfortunately, methods are often restricted to general, well-known and commonly used assessments, which
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are easily performed, interpretable and comparable between individuals or groups (e.g. questionnaires) but
which neglect potentially relevant (interactions between) individual, unique “traits” (i.e. underlying
explanatory mechanisms) to finally ensure personalised treatment.
Looking back
Given our increasing understanding of COPD as a heterogeneous and complex disease, it is important to
accentuate that, in this context “complex” means that COPD has a number of intrapulmonary and
extrapulmonary components whose dynamic interactions over time are not linear, whereas
“heterogeneous” indicates that not all of these components are present in all individuals at any given
time-point [12]. An overview of methods assessing and involving this heterogeneity and complexity will be
discussed below and are illustrated in table 1.
Global Initiative for Chronic Obstructive Lung Disease
To honour the 20th anniversary of the Global Initiative for Chronic Obstructive Lung Disease (GOLD),
RODRIGUEZ-ROISON et al. [13] recently summarised the key differences of the major revisions of the GOLD
documents (2001–2017) clearly demonstrating a shift from a solely spirometric staging system to a more
extensive classification.
The 2006 GOLD statement classified COPD patients into four groups (GOLD stages I to IV), exclusively
based on the degree of airflow limitation [22]. Since this parameter is only poorly to moderately associated
with disease activity, progression and prognosis, the 2011 GOLD strategy started classifying patients into
four new groups (GOLD groups A to D) based on the combination of the degree of airflow limitation and
the number of exacerbations and the severity of symptoms [23]. The latest 2017 GOLD strategy separated
spirometric assessment from symptoms and risk evaluation aiming to facilitate tailored treatment to the
needs of the individual patient and proposed patients’ symptoms and exacerbation history alone to assign
patients to ABCD categories [9]. However, exacerbation history as a decisive parameter has not been
validated; a recent study showed that exacerbation frequency is highly variable over time, while the
frequent exacerbator phenotype (two or more exacerbations every year) was the most uncommon one [24].
Extrinsic factors might further impact exacerbation occurrence making these events difficult to predict
[24]. Furthermore, variations may occur in the pathophysiology of exacerbations over time in an
individual patient, which is a currently unexplored topic and adds to the complexity of COPD. Finally, the
choice of symptom measure and/or cut-off point used impacts the classification of patients with COPD
into GOLD A/C or B/D groups which can result in misclassification and, consequently, different treatment
recommendations [25].
Multidimensional indices
During the past decade, multidimensional indices including medical, pathophysiological, symptomatic
and/or psychological parameters have been developed as screening instruments [11, 15] or prognostic
markers for COPD [10]. Prognostic performance of multidimensional indices providing composite scores
(e.g. the BODE (body mass index, airflow obstruction, dyspnoea and exercise) index [14]) is moderate to
good, but it is still unknown if they improve COPD disease management or patients’ health [10]. Another
example of providing a more detailed patient profile is the Nijmegen Clinical Screening Instrument which
is an empirically composed battery of existing instruments providing a detailed picture of 21 dimensions
of an individual patient’s integrated health status and thus guides individualised treatment [15, 26]. It has
been suggested that, on the one hand, multidimensional indices might be useful in grouping patients in
terms of clinically relevant outcomes; and on the other hand, it is also possible that by grouping patients
this way distinct features of the disease might be grouped, blurring the heterogeneity and understanding of
the disease [27]. Indeed, it has been suggested that prognostic indices cannot identify or substitute groups
or phenotypes since patients sharing a similar prognosis based on a single score might not be considered
as belonging to the same phenotype [28]. As further clarified, they are not risk factors or phenotypes but
useful measures of disease severity to establish prognosis [29].
Phenotypes
A phenotype has been defined as “a single or combination of disease attributes that describe differences
between individuals with COPD as they relate to clinically meaningful outcomes (symptoms,
exacerbations, response to therapy, rate of disease progression, or death)” [27].
In the 1960’s, the terms “blue bloater” and “pink puffer” came up to describe patients with chronic
bronchitis and emphysema, respectively [30], marking the very beginning of phenotyping COPD.
Commonly used phenotypes are often based on pulmonary disease characteristics like the presence of
emphysema, chronic bronchitis, overlap asthma-COPD and/or (in)frequent exacerbations [31]. MIRZA and
BENZO [32] recently described several “easily identifiable” and “clinically meaningful” COPD phenotypes
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TABLE 1 Overview of strategies to classify, assess or group patients with chronic obstructive pulmonary disease (COPD)
Goal Advantages Shortcomings Heterogeneity Complexity
GOLD Classification of COPD
based on the degree of
airflow obstruction (up
to 2011), in combination
with symptoms/
exacerbations (2011–
2017), or symptoms/
exacerbations only
(2017)
From an FEV1 centric view to
a more extensive approach
and a more prominent role
of symptoms/individual
measures [13]
Parameters assessing COPD
severity still very limited; ignoring
variability and unpredictability of
symptoms/exacerbations/
hospitalisations; proposed cut-off
points for symptom measures
mostly expert driven
Separation of airﬂow
limitation
from clinical parameters
(GOLD 2017) [9] clarifies
what is being evaluated
and ranked and might
facilitate more precise
treatment
Not addressed
Multidimensional
indices
Prognostic indices to
predict survival;
screening instruments
As prognostic markers: useful
in grouping patients in
terms of clinically relevant
outcomes [14]; as a
screening instrument:
multidimensional
assessment of COPD
[11, 15]
Identification of substitute groups or
phenotypes only by selected
variables included in the
respective index; consist of a
limited number of variables; have
not been developed to guide
future treatment [16]
Multidimensional
assessment, including, for
example, medical,
pathophysiological,
symptomatic [14] and/or
psychological [15]
parameters
Not addressed
Phenotypes Grouping patients based
on certain
characteristics
From “blue bloater” and “pink
puffer” to complex cluster
analyses identifying existing
and novel phenotypes
Cluster analyses only moderate
reproducibility, clinical application
disputable [17], considerable
overlap between phenotypes for
some specific attributes
As a screening instrument:
differentiating between
individuals by assessing/
clustering various
characteristics
Not addressed
COPD control
panel
Assessment of different
elements of the disease
Assessing at least three
dimensions (severity,
activity and impact), can be
customised to the need of
the patient [18]
Unclear which characteristics
should exactly be assessed, which
methods, cut-off points, etc.
should be used
Multidimensional
assessment; might serve
as a “clinical decision
support system” (by
selecting/classifying
patients)
Not addressed
Treatable traits Label-free, precision
medicine approach
COPD management based on
individual treatable
characteristics (intra- and
extrapulmonary treatable
traits, treatable behaviour/
lifestyles (including
patients’ environment)) [19]
Separate assessment of treatable
traits results in fragmented
treatment; frequency of
assessment and
inter-relationships between traits
unknown
Assessing heterogeneity by
individual unique traits
Not addressed
Pulmonary
rehabilitation
Personalised, holistic
approach of treatable
traits
Comprehensive intervention
based on a thorough
assessment taking into
account the combination
and interaction between the
(treatment of) individual
treatable traits [20]
Applicability in routine clinical
practice (dependent on
organisational structure, facilities,
workforce, funding, etc.) is
challenging; poor referral and
compliance; not all traits are
always addressed (yet); mostly
non-pharmacological generic
interventions
Assessing heterogeneity by
individual unique traits
Assessment of complex
interactions of physical,
psychological, social and
environmental factors by
dedicated, transdisciplinary
teams being able to respond
flexibly as well as accept
unpredictability and
non-linear outcomes [21]
GOLD: Global initiative for chronic Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s.
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and added the upper lobe-predominant emphysema phenotype, rapid decliner phenotype, comorbid
COPD phenotype, physical frailty phenotype and emotional frailty phenotype with the purpose of guiding
personalised and effective care.
Using phenotypes to classify and/or screen patients might be an interesting alternative to currently used
criteria for recruiting patients in clinical trials [28] and might help optimising (non)pharmacological
integrated treatment [33], but the application into routine clinical practice and to facilitate personalised
medicine is questionable since phenotypes still group patients and therefore potentially ignore individual
characteristics. Indeed, the same clinical phenotype could result from different endotypes [34].
Clustering patients
Cluster analysis has been defined as a group of analysis techniques that aim to organise information so
that heterogeneous subjects can be classified into homogeneous subgroups (i.e. clusters) which may further
identify novel phenotypes [35]. To identify phenotypes, clinical features, imaging, pulmonary function,
exercise tests, biomarkers and comorbidities may be used [28].
However, the current understanding of phenotypes might be biased since there is a significant
heterogeneity in the selection of subjects and statistical methods used, as well as a lack of information
about different COPD populations (including women, never-smokers and those with mild disease) which
challenges the clinical application of the defined phenotypes [28, 36]. Indeed, a recent study assessing the
reproducibility of COPD clustering subtypes concluded that identical clustering analyses across multiple
COPD cohorts showed modest reproducibility [17]. Furthermore, it is known that subtypes (phenotypes)
might change over time [37], underlining the need for continuous evaluation of a given phenotype.
Finally, a systematic review showed that the number of phenotypes ranged from two to five [36], which
seems rather limited for personalised approaches. Nonetheless, phenotyping and/or clustering patients
might be a useful screening procedure differentiating between individuals; further validation of statistical
clustering techniques is needed to refine and elaborate (existing) clusters.
The COPD control panel
AGUSTI and MACNEE [18] suggested to use a “control panel” including at least three dimensions (severity,
activity and impact) to assess different elements of the disease (in a single patient at a given time-point) to
visualise the complexity of COPD and to move COPD management towards personalised medicine. These
three modules containing biological and clinical variables can provide complementary and relevant
information for the proper management of the individual patient. It can be customised to the needs of the
patient and the available resources (e.g. rural versus urban healthcare centres and primary versus
specialised care) [38]. The “control panel” may further serve as a clinical decision support system [39].
However, which treatable clinical characteristics should exactly be assessed and which methods and cut-off
points should be used has not yet been formally validated. Furthermore, a control panel does not reveal
any complex interactions, possibly resulting in fragmented treatment [7].
Treatable traits
Based on the control panel, the appellation “treatable traits” has recently been introduced which refers to a
“label-free, precision medicine approach to the diagnosis and management of chronic airway diseases” [19],
while precision medicine is defined as “treatments targeted to the needs of individual patients on the basis
of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from
other patients with similar clinical presentations” [40].
As suggested earlier, patients with COPD should be assessed and treated according to their individual treatable
characteristics, which is further likely to improve clinical outcomes [41]. Management of airway diseases
based on individual treatable traits present in each subject has been suggested: “these traits can be ‘treatable’
based on ‘phenotypic’ recognition (and thereby probabilistic evidence based on positive and negative
predictive values) or on deep understanding of the critical causal pathways (e.g. true ‘endotypes’)” [19].
The authors suggested a variety of treatable traits (which can coexist) summarised into three groups:
pulmonary treatable traits, extrapulmonary treatable traits and treatable behaviour/lifestyle risk factors.
Remarkably and importantly, the patients’ environment (family and social support) has been included as a
distinct treatable trait [19]. Assessing “treatable traits” has been suggested as a way to facilitate precision
medicine, although individual variability in genes is not part of this disease treatment. Furthermore, this
approach focusses on the assessment of several separate traits [18, 19], while integrated holistic approaches
are needed to tackle the complexity of every unique patient. Furthermore, a global outline of treatable
traits consequently rather leads to general treatment recommendations without the suggested “deep
understanding of the critical causal pathways” [19] than facilitates personalised medicine understanding
evident complexity of the disease. Finally, besides the assessment of specific traits, the evaluation of
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outcomes and reassessment of treatable traits during follow-up, including readjustment of treatment as
well as new outcome assessment, are essential.
In summary, the multidimensional approaches illustrated above are assessing the heterogeneity of the
disease, rather than tackling the complexity of the disease. One tool can neither guarantee a personalised
approach nor provide a patient profile enabling individualised treatment [42]. A control panel or treatable
traits approach is largely driven by disease characteristics, resulting in fragmented treatment of identified
traits [7]; a list of variables does not reveal complex interactions consequently leading to patient-tailored
treatment.
Looking forward
Complex goals need complex solutions [43]. Personalised medicine or treatment strategies require
personalised assessment including pulmonary and extrapulmonary as well as personal, social and
environmental factors. As shown by a factor analysis including 16 demographic and clinical characteristics
(i.e. age, body mass index, pre-bronchodilator forced expiratory volume in 1 s (FEV1), pre-bronchodilator
FEV1/forced vital capacity or FEV1/vital capacity, FEV1 reversibility, St Georges’ Respiratory Questionnaire
total score, months since first COPD symptoms, systolic and diastolic blood pressure, pulse, morning peak
expiratory flow (PEF), PEF variability, scores of breathlessness, cough, sleep disturbance and reliever use), six
factors of characteristics explained ∼60% of COPD heterogeneity [44], resulting in 40% which still remained
unexplained. Other relevant characteristics (e.g. functional performance, personal or social factors and
biomarkers) are missing in this analysis and might explain part of the remaining variance. Thus personalised
and holistic approaches are needed to facilitate a full understanding of (the impact of) the disease.
Towards personalised and holistic approaches
When personalisation is viewed as “tailoring medicine to patient preferences, further work is needed
regarding: revealed preferences, e.g. treatment (non)adherence; stated preferences, e.g. risk interpretation
and attitude; consideration of heterogeneity in preferences; and the appropriate framework to incorporate
non-health benefits” [45]. Personalised approaches require holistic approaches; an integrated, all-embracing
understanding of the disease, since COPD is the end result of a complex set of interactions between the
environment, the genetic background of the individual and biological networks [38]. Indeed,
“personalised medicine must consider human beings as composed of and operating within multiple
interacting and self-adjusting systems where illness arises from the dynamic interaction within and
between these systems” [7].
Below, we will discuss three examples of complex interactions of (and within) disease characteristics
demonstrating the (underlying mechanisms of) individual, unique “traits”.
Example 1: functional status
Patients with COPD report a variety of problematic activities in daily life [46, 47] of which walking is most
frequently reported [46]. Field-based walking tests are the most commonly used and reported tests.
However, these tests are a quantitative identification of the patient’s walking abilities rather than a
qualitative description of the individual’s performance. Generally, these tests do not consider problems or
inconveniences patients perceive during the particular activity. Research has shown that patients with
COPD are at increased risk for frailty [48], have an impaired balance [49] and an altered gait pattern
compared to controls [50, 51]. Thus, understanding the individual’s limitations would enhance the
possibilities for a personalised approach, e.g. sophisticated gait analyses.
Alternatively, for instance, the Canadian Occupational Performance Measure (COPM) might be used to
assess functional performance [20]. The COPM is an individualised scale assessing patients’ problematic
activities of daily life. Patients have to rate the perceived performance as well as satisfaction for relevant
problematic activities [52], which may provide a better understanding of the individual physical limitations
as well as abilities. A qualitative study revealed social barriers (lack of time, overprotective family
members) and enablers (social support) and a variety of personal barriers and enablers (figure 1) that
limit and encourage, respectively, participation in physical activity in patients with COPD. The authors
conclude that “it is important to understand the patient-specific social cognitive influences on physical
activity participation” which might consequently facilitate individually tailored management planning [53].
This study clearly demonstrates the necessity to detect and understand underlying individual factors to
finally enable personalised medicine and respond to the individual patient’s needs.
Example 2: patients’ social network
As already illustrated in figure 1, patients’ physical activity can be affected by their social network [53], i.e.
by their resident loved ones. Indeed, patients with an active loved one are also more active themselves [54].
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A recent study demonstrated that structural support (e.g. living status, having a partner, having a
caregiver) is associated with higher levels of physical activity and greater participation in pulmonary
rehabilitation in patients with COPD while higher functional support was associated with, for instance,
lower odds of smoking [55]. Furthermore, patients with more perceived social support experienced fewer
depressive symptoms through the use of problem-oriented coping strategies [56]. Thus, the patients’ home
environment plays an important role in the process of disease management emphasising the need to
include it as a relevant part for treatment strategies [57]. However, the process of informal caregiving is
complex [58]. For instance, partners were often not able to identify patients’ most important problematic
activities [59] and are often current smokers and have (undiagnosed) morbidities [60]. Unfortunately,
caregivers often feel unsupported and are often overlooked as important members of the interdisciplinary
treatment team [61]. Thus, patients, caregivers, healthcare providers and society are all engaged in
managing life with COPD [62], emphasising the need for holistic models considering patient’s family and
social context [63].
Example 3: patient-reported outcomes
Facilitating personalised disease management requires the assessment of individual parameters, as outlined
above. Patient-Reported Outcome (PRO) is “any report of the status of a patient’s health condition that
comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone
else” [64]. The importance of PRO’s in clinical practice as well as research will substantially increase in the
coming years [65].
Linking to example 2, patients with more perceived social support experienced fewer depressive symptoms [56].
Anxiety and depression have been identified as one of the most important COPD-related comorbidities [66].
However, anxiety and depression are most commonly assessed and consequently most commonly
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FIGURE 1 Examples of personal barriers and enablers that both encourage and limit participation in physical activity for patients with chronic
obstructive pulmonary disease (COPD). PA: physical activity. Reproduced from [53] with permission.
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reported (to define psychological impairment) raising the interest and need to assess other underlying
mechanisms or individual psychological factors which may play a central role in COPD management. For
instance, patients with symptoms of anxiety and depression reported a lower use of active confronting
coping (i.e. actively seeking information, solutions and/or support) [67]. A qualitative study revealed
that patients are struggling with acceptance of their disease which even precludes patients from
progress during their pulmonary rehabilitation programme [68]. Indeed, acceptance of the disease is
associated with behaviour change [26]. Furthermore, acceptance of the diagnoses and limitations, having a
realistic disease understanding and developing a rational response to the disease are ways of enabling
taking control [69]. Another considerable outcome is emotional intelligence, i.e. the capacity to understand
and manage personal thoughts and feelings, as well as to positively influence interpersonal communication
and social well-being, which has been shown to be associated with self-management abilities and health
status [70].
Furthermore, health status measurement has previously been described as an essential process which is
“no more ‘soft’ or ‘touchy-feely’ than any well taken clinical history” [71], supporting health status as an
increasingly important PRO in the assessment of COPD [9]. Indeed, health status has been shown to be
associated with exacerbations, hospitalisations and dying [72]. Also fatigue has been shown to be
associated with hospitalisation risk [73]. Although fatigue is a common and important symptom in
patients with COPD [74, 75], it is often assessed related to exercise testing. Furthermore, it is still
underdiagnosed and consequently undertreated [76]. As it has been described as a “central driver of
functional disability, to the same extent as dyspnoea” [77] (linking to example 1), recent studies emphasise
the importance of assessing fatigue as a separate outcome [77, 78].
The patient’s (unbiased) experiences and expectations about the patient’s own life, values and preferences
play a central role in healthcare, since they are the ones living with the disease and are ultimately
responsible for their lives. Indeed, as suggested by a Dutch report, key concepts of future healthcare are
encouraging patients’ functionality and independency, adaptability and flexibility as well as control,
autonomy and self-management [79]. Thus, Patient Reported Experience Measurements assessing the
beneficial values for the patient are becoming relevant outcome parameters [80]. Indeed, rating and
understanding patients’ satisfaction and interpreting their feedback (co-creation) provides important
insights and outcomes to finally improve healthcare services [81].
The non-linear and consequently poorly predictable treatment responses caused by the disease [3] further
support the dynamic interactions as demonstrated above. SPRUIT et al. [3] demonstrated that responses to
regular outcomes in patients with COPD completing pulmonary rehabilitation are differential and
concluded that “choosing only one or two outcomes as key performance indicators seem to ignore the
clinical complexity of rehabilitating patients with COPD”. It is not about severity but complexity of the
disease.
Pulmonary rehabilitation
Pulmonary rehabilitation has been defined as a “comprehensive intervention based on a thorough patient
assessment followed by patient-tailored therapies which include, but are not limited to, exercise training,
education, behaviour change, designed to improve the physical and psychological condition of people with
chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviours” [20].
The overall goal of pulmonary rehabilitation is “to return the patient to the highest possible capacity and
to contribute to achieve the individual’s maximum level of independence and functioning in the
community” [21]. Pulmonary rehabilitation, suggested as a future cornerstone of COPD management [82],
provides an appropriate setting tackling the complexity outlined above by offering a personalised, holistic
approach which was initially discussed more than 40 years ago. In 1974, the American College of Chest
Physicians defined pulmonary rehabilitation as an individually tailored, multidisciplinary programme
through accurate diagnosis, therapy, emotional support and education [83]. In 1994, the National Institute
of Health defined pulmonary rehabilitation as a multidimensional continuum of services for the patient
and family supplied by an integrated team of specialists in complementary disciplines [84].
Pulmonary rehabilitation is a dynamic, individualised, integrated intervention requiring the full range of
(medical) expertise, technical skills and specialised facilities addressing carefully identified treatable traits.
It is offered by a dedicated team which works within, as well as across, disciplines to realise the individual
goals of the unique patient. Figure 2 demonstrates the core process of pulmonary rehabilitation.
Appropriate patient selection and an integrated assessment is crucial for successful treatment. Careful
identification of treatable traits and treatment goals must form the start of every pulmonary
rehabilitation programme. Based on the degree of complexity, a modular treatment programme is
composed. Each individualised programme is followed by an outcome measurement of the different
domains as described [21].
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Focus: the unique patient
Pulmonary rehabilitation emphasises and relies on the central role of the patient [21]. Especially in
chronic diseases, the patient, as a specialist of his own life [85], is an important member of the treatment
team: it is not about curing, it is about life-long caring and learning to live with the disease, handling
symptoms and accepting limitations. Indeed, enhancing self-management and empowering patients as well
as achieving the individual’s maximum level of independence are important goals of pulmonary
rehabilitation [20, 21, 86]. Self-management, as also included in the definition of health [87], supports the
concept of “positive health” [88], emphasising possibilities instead of limitations. We need to qualify
patients’ abilities instead of quantify their harm.
Healthcare providers involved in the management of COPD must be encouraged to target the unique
needs and abilities reflecting the individual complexity of every patient (consequently) stimulating
anticipation [42] and to consider the patient’s social/home environment [89]. In future, and to enhance
self-management, healthcare providers are expected to be competent coaches and advisors with
compassion and humanity as key elements in their daily work [80].
In pulmonary rehabilitation, tailored treatment goals are composed not only in collaboration with other
professionals but, probably even more importantly, in discussion with the patient [21]. Shared decision
making as “an approach where clinicians and patients share the best available evidence when faced with
the task of making decisions, and where patients are supported to consider options, to achieve informed
preferences” plays a crucial role in personalised treatment approaches. Due to the visual presentation of
FIGURE 2 The process of a patient-tailored programme including the three core processes (baseline assessment, tailored treatment and outcome
assessment). An integrated baseline assessment identifying the complexity of the disease is followed by a treatment programme composed of at
least all basic modules. Depending on the complexity, specific burden-driven modules can be added. Each individualised programme is followed
by an outcome measurement. Examples of adaptations include degree of self-management and coping. Reproduced from [21] with permission.
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the results to the health professional as well as the patient, the Nijmegen Clinical Screening Instrument
might support the process of shared decision making [26].
Furthermore, a recent study showed that patients were not willing to accept the burden of treatments
where they perceived minimal benefit [90], demonstrating the importance of clear information about
benefits and impact of a given treatment. Indeed, in case of complex adaptive systems, a small change can
have a large effect in behaviour [91]. Importantly, patients’ behaviour is partly determined by unique and
adaptive responses to environmental stimuli [91] underlining the importance of creating a safe and
realistic environment for disease management strategies.
Yet, there are also some relevant limitations. Pulmonary rehabilitation is mostly a non-pharmacological
generic intervention underlining the necessity to integrate medicine and pulmonary rehabilitation by, for
instance, implementing optimal treatment of comorbidities in relevant subgroups, applying noninvasive
ventilation during exercise training in patients with hyperinflation and exercise-induced desaturation,
using anabolic steroids in the treatment of cachexia and/or combining pulmonary rehabilitation with lung
volume reduction intervention in eligible patients. Thus, pulmonary rehabilitation is a dynamic,
individualised, integrated intervention tackling respiratory and non-respiratory treatable traits. This
concept of pulmonary rehabilitation is far away from the eroded approach of pulmonary rehabilitation
described in some guidelines, limiting pulmonary rehabilitation to exercise training and self-management
instructions [92, 93].
Conclusion
COPD management is challenging and requires advanced, sophisticated strategies meeting the patient’s
individual needs. Due to the heterogeneity and complexity of the disease leading to non-linear and
consequently poorly predictable treatment responses, multidimensional patient profiling is crucial to
identify the right COPD patient for the right treatment [3]. Transdisciplinary management programmes
realising real benefits by integrating concepts of adaptive systems need to address the physical, emotional
and social condition of the individual patient [94]. Dynamic, personalised and holistic approaches, i.e.
pulmonary rehabilitation, are needed to tackle the multifaceted disease starting from the patient’s
perspective to finally ensuring personalised medicine and value-based healthcare: “to cope with escalating
complexity in healthcare, it is necessary to abandon linear models, accept unpredictability, respect
autonomy and creativity, and to respond flexibly to emerging patterns and opportunities” [21].
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